You mean the new breed of biotech utilising a modern agile approach For funding from inflection point to inflection point whilst and maintaining a flexible approach and pivot points for new trial collaborations?
the science is good and after years we had the first real data confirming this - just 7 months ago - even though many of us suggested the clues were there - turns out for GBM at least we are better than the standard of care!
we have collaborations with worlds top oncology research organisations and in a few weeks more news going plus in a few months we enter the GBM Agile trial a pivotal study for FDA approval
I think I’ll follow the worlds leading scientists in oncology and a management team which continues to set relationships and Potentially open new trials whilst still funding 6 trials over years with some 11 million in the bank... over a posters or two who’s shrill calls from the wild eco from one to the other.
it’s all about the science - it always has been. But we also have a management team who are seen to be leading the vanguard in modern funding models and research trial structures.
granted its difficult for some to grasp... meanwhile each day brings us closer to a readout
KZA Price at posting:
49.5¢ Sentiment: Buy Disclosure: Held
